UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 287,911 shares of the company's stock after selling 80,221 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.48% of Protagonist Therapeutics worth $11,113,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PTGX. Covestor Ltd grew its holdings in Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after purchasing an additional 1,612 shares during the period. KBC Group NV boosted its stake in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after acquiring an additional 737 shares during the period. New Vernon Capital Holdings II LLC acquired a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $118,000. Nisa Investment Advisors LLC raised its stake in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after acquiring an additional 295 shares during the period. Finally, Cibc World Markets Corp bought a new stake in Protagonist Therapeutics in the 4th quarter valued at $211,000. 98.63% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 4,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This represents a 23.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 1,756 shares of the firm's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the sale, the chief financial officer now directly owns 61,065 shares in the company, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,173 shares of company stock valued at $3,461,180. 4.90% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock traded up $1.13 during trading on Tuesday, hitting $51.28. The company had a trading volume of 684,269 shares, compared to its average volume of 886,456. The firm has a market capitalization of $3.18 billion, a P/E ratio of 19.28 and a beta of 2.65. Protagonist Therapeutics, Inc. has a one year low of $28.36 and a one year high of $60.60. The stock's 50-day moving average price is $45.26 and its 200 day moving average price is $42.69.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The company had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on PTGX. BMO Capital Markets lifted their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Wall Street Zen lowered shares of Protagonist Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. JPMorgan Chase & Co. increased their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. JMP Securities restated a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.